Here’s a polished English translation of the Chinese title: **Menarini Group Presents New Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting**

• Data covers seven presentations across solid tumors and hematologic malignancies, providing the latest information on the potential benefits these therapies may offer patients. 

• ELEVATE study data on the elacestrant plus capivasertib regimen will highlight its potential in mBC combination therapy, as well as the latest progress in the elacestrant clinical development program, including its potential role as a single-agent adjuvant therapy option for breast cancer.

• Stemline’s partner Karyopharm Therapeutics will deliver a late-breaking oral presentation from the Phase 3 SENTRY trial of Selinexor in myelofibrosis

“For medical and pharmaceutical industry media only” 

Florence, Italy and New YorkMay 25, 2026 /PRNewswire/ — Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformative oncology therapies to cancer patients, announced today that new data related to elacestrant and tagraxofusp will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

New data from the Phase 1/2 ELEVATE study will be provided, exploring the safety and preliminary efficacy of elacestrant in combination with capivasertib in patients with ER+/HER2- PI3K/AKT/PTEN-pathway altered metastatic breast cancer (mBC). Additional details on ongoing elacestrant combination studies in the advanced setting will be shared: ADELA (pivotal Phase 3 in combination with everolimus), ELECTRA (Phase 1b/2 in combination with abemaciclib in patients with brain metastases), and CAPELA (Phase 2 in combination with capecitabine). Finally, the latest progress from the ELEGANT study, exploring elacestrant as an adjuvant therapy for high-risk, lymph node-positive early breast cancer, will be presented at the meeting.

Also being presented are new Phase 2 tagraxofusp combination data in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), to be presented by Naveen Pemmaraju, MD, Professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center. Additionally, Stemline’s partner Karyopharm Therapeutics will present a late-breaking oral presentation from the Phase 3 SENTRY trial of Selinexor in JAKi-naïve myelofibrosis (MF). Selinexor is marketed by Karyopharm Therapeutics in the U.S. and by Stemline in the EU.

“The extensive oncology data to be presented, spanning both solid tumors and hematologic malignancies, underscores our commitment to addressing the most difficult-to-treat cancers with high unmet need,” said Elcin Barker Ergun, CEO of the Menarini Group. “Our focus remains on accelerating innovation to deliver transformative targeted therapies that provide meaningful advances for patients and the healthcare community dedicated to their care.”

Full details on the upcoming presentations are provided below: